Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
13
02
2020
revised:
09
06
2020
accepted:
04
07
2020
pubmed:
15
8
2020
medline:
29
6
2021
entrez:
15
8
2020
Statut:
ppublish
Résumé
Circulation of hepatitis E virus (HEV) in areas where plasma is sourced for the manufacture of plasma-derived medicinal products (PDMPs) has prompted verification of HEV clearance. HEV exists as quasi lipid-enveloped (LE) and non-lipid-enveloped (NLE) forms, which might be of relevance for HEV clearance from manufacturing processes of antibody-containing PDMPs with solvent/detergent (S/D) treatment upstream of further clearance steps. Presence of different HEV particles in stocks used in clearance studies was investigated, with nanofilters graded around the assumed HEV particle sizes and by gradient centrifugation. HEV removal by 35-nm nanofiltration was investigated in the presence or absence of HEV antibodies, in buffer as well as in immunoglobulin (IG) manufacturing process intermediates. HEV particles consistent with LE, NLE, and an "intermediate" (IM) phenotype, obtained after S/D treatment, were seen in different HEV stocks. In the absence of HEV antibodies, log reduction factors (LRFs) of 4.0 and 2.5 were obtained by 35-nm nanofiltration of LE and IM HEV, consistent with the larger and smaller sizes of these phenotypes. Addition of HEV antibodies enhanced IM HEV removal around 1000-fold (LRF, 5.6). Effective (LRF, >4.8 and >4.0) HEV removal was obtained for the nanofiltration processing step for IG intermediates with varying HEV antibody content. HEV spikes used in clearance studies should be carefully selected, as differences in physicochemical properties might affect HEV clearance. Antibody-mediated enhancement of HEV nanofiltration was demonstrated in IG process intermediates even at low HEV antibody concentration, illustrating the robustness of this manufacturing step.
Sections du résumé
BACKGROUND
Circulation of hepatitis E virus (HEV) in areas where plasma is sourced for the manufacture of plasma-derived medicinal products (PDMPs) has prompted verification of HEV clearance. HEV exists as quasi lipid-enveloped (LE) and non-lipid-enveloped (NLE) forms, which might be of relevance for HEV clearance from manufacturing processes of antibody-containing PDMPs with solvent/detergent (S/D) treatment upstream of further clearance steps.
STUDY DESIGN AND METHODS
Presence of different HEV particles in stocks used in clearance studies was investigated, with nanofilters graded around the assumed HEV particle sizes and by gradient centrifugation. HEV removal by 35-nm nanofiltration was investigated in the presence or absence of HEV antibodies, in buffer as well as in immunoglobulin (IG) manufacturing process intermediates.
RESULTS
HEV particles consistent with LE, NLE, and an "intermediate" (IM) phenotype, obtained after S/D treatment, were seen in different HEV stocks. In the absence of HEV antibodies, log reduction factors (LRFs) of 4.0 and 2.5 were obtained by 35-nm nanofiltration of LE and IM HEV, consistent with the larger and smaller sizes of these phenotypes. Addition of HEV antibodies enhanced IM HEV removal around 1000-fold (LRF, 5.6). Effective (LRF, >4.8 and >4.0) HEV removal was obtained for the nanofiltration processing step for IG intermediates with varying HEV antibody content.
CONCLUSION
HEV spikes used in clearance studies should be carefully selected, as differences in physicochemical properties might affect HEV clearance. Antibody-mediated enhancement of HEV nanofiltration was demonstrated in IG process intermediates even at low HEV antibody concentration, illustrating the robustness of this manufacturing step.
Identifiants
pubmed: 32794187
doi: 10.1111/trf.16014
pmc: PMC7754313
doi:
Substances chimiques
Hepatitis Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2500-2507Subventions
Organisme : This study was funded by the Austrian Research Promotion Agency (FFG) and Baxter AG, Vienna, Austria, now part of the Takeda group of companies.
Informations de copyright
© 2020 Baxter AG, part of Takeda. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Transfusion. 2016 Oct;56(10):2532-2537
pubmed: 27453197
Vox Sang. 2010 Jan;98(1):12-28
pubmed: 19660029
J Virol. 2017 Oct 27;91(22):
pubmed: 28878075
Biochimie. 2017 Oct;141:70-79
pubmed: 28483690
J Clin Microbiol. 2010 Apr;48(4):1112-25
pubmed: 20107086
J Infect Dis. 2019 Jan 7;219(2):245-253
pubmed: 30137432
N Engl J Med. 2009 Sep 3;361(10):1025-7
pubmed: 19726781
Transfusion. 2019 Mar;59(3):1024-1034
pubmed: 30702157
Transfusion. 2017 Dec;57(12):2958-2964
pubmed: 28833188
Transfusion. 2006 Jul;46(7):1143-51
pubmed: 16836561
Emerg Infect Dis. 2013 May;19(5):729-35
pubmed: 23647659
Gastroenterology. 2018 Jan;154(1):211-223.e8
pubmed: 28958858
J Gen Virol. 2017 Nov;98(11):2645-2646
pubmed: 29022866
Biotechnol Bioeng. 2015 Mar;112(3):633-7
pubmed: 25220795
Vox Sang. 2008 Aug;95(2):94-100
pubmed: 18714441
J Infect Dis. 2019 Feb 23;219(6):916-924
pubmed: 30325442
Vox Sang. 2008 Apr;94(3):184-92
pubmed: 18167162
Transfusion. 2017 Mar;57(3pt2):790-796
pubmed: 27731495
Front Med (Lausanne). 2018 Feb 01;5:5
pubmed: 29450199
Transfusion. 2016 Feb;56(2):383-91
pubmed: 26399175
Biologicals. 2016 Sep;44(5):403-11
pubmed: 27461242
J Gen Virol. 2014 Oct;95(Pt 10):2166-2175
pubmed: 24970738
Transfusion. 2020 Nov;60(11):2500-2507
pubmed: 32794187
PLoS One. 2019 Jun 7;14(6):e0216826
pubmed: 31173594